Since the first description of 'epitheliomas' by von Graefe in 1860, many papers have described squamous epithelial neoplasia of the surface of the eye. after several attempts were made to classify the varying presentations of these lesions, the term ocular surface squamous neoplasia (oSSN) was introduced in 1995 1 as a way to describe all squamous neoplastic lesions of the conjunctiva and cornea. This includes benign, noninvasive papillomas, pseudoepitheliomatous hyperplasia, and benign hereditary intraepithelial dyskeratosis, as well as conjunctival-corneal intra-epithelial neoplasia (cciN), squamous cell carcinoma (Scc), and mucoepidermoid carcinoma. 2 The american Joint committee on cancer classification (aJcc) established a TMN system for classifying oSSN, 3 which has been useful in standardizing the reporting of various treatment options.
smoking, ocular surface injury, chemicals (petroleum products, beryllium, trifluridine, arsenic), and vitamin a deficiency. 2 
Treatment
historically, oSSN has been treated surgically. early case series reported recurrence rates of 15 % to 52 %.
1 the Shields group reported a 'notouch' method of larger excised margins (2 mm on cornea; 4-5 mm on conjunctiva) with absolute alcohol and adjuvant cryotherapy in 1997, with lower recurrence rates. 12 the challenges of complete surgical excision in patients with extensive tumors, in addition to the high recurrence rates in some series, led to a search for nonsurgical treatment modalities. in addition to avoiding surgery, topical agents treat clinically unapparent disease. Due to the theoretic advantages of topical chemotherapy, multiple agents have been used in both the primary and adjuvant treatment of oSSN.
Mitomycin C mitomycin c (mmc) is an antibiotic with antitumor activity that is isolated from Streptomyces spp. it functions as an alkylating agent leading to the cross-linking of DNa, thereby inhibiting DNa synthesis. 13 initially it was used as an intravenous treatment of many different solid organ tumors, but it has also been found to be effective as a topical agent. it was first reported as a therapy for corneal intraepithelial neoplasia in 1994 by Frucht-pery in 23 in the same series of patients, the risk for developing limbal stem-cell deficiency after treatment with mmc was reported to be 12 %. 23 it is recommended to allow for complete healing of conjunctival/corneal tissues after biopsy or excision prior to initiating mmc topical therapy to reduce the risk for corneo-scleral melt. confocal analysis of the corneal endothelium in eyes treated with mmc for oSSN demonstrated no significant change in cell count after therapy. 24 Despite the lack of randomized studies involving mmc treatment of oSSN there is sufficient evidence to suggest efficacy as both an adjuvant and primary therapy, although the risk for limbal stem cell deficiency may be unacceptably high in patients that could potentially be treated with other modalities. RNa and therefore protein synthesis, and it has been shown to affect the actin cytoskeleton. 25 refractory to mmc therapy. 30 conversely, it has also been reported that 5-FU treatment failures can respond to mmc. 28 Side effects attributed to 5-FU topical therapy for oSSN are similar to those of mmc. they commonly include conjunctival injection, keratopathy, ocular pain, and skin irritation. 22 as previously mentioned, in the patients who underwent short pulses of therapy, these side effects were minimized. Some studies indicate that the p38 map kinase pathway may play a role in the anti-tumor properties of interferons. 32 Studies in skin cancer show a downregulation of interleukin (il)-10, an immunosuppressive cytokine found in some skin cancers, 33 and an upregulation of il-2 and iFN-gamma, which aid in t-cell response. 34 interferons have also been
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shown to modulate the regulation of oncogenes, including p53. of the 14 patients who underwent primary surgical excision using the Shields technique there were no recurrences. 43 one of the likely reasons for the increase in iFNα-2B use is the relative paucity of adverse effects. in the Shields series, side effects included hyperemia, irritation, follicular conjunctivitis, and superficial punctate keratitis, which occurred in less than 5 % of the patients. 41 in the US, topical iFNα-2B is a more expensive therapy than 5-FU and mmc, but with the decreased incidence and severity of adverse effects, increased patient tolerance, and acceptable efficacy it is a viable topical option for the treatment of oSSN.
Other Potential Therapies
other nonsurgical treatments may be viable options as well. one that has recently been reported is anti-vascular endothelial growth factor (veGF) therapy. antibodies against veGF, a pro-angiogenic signal, were originally developed as an antitumor medication and have been used to treat colon, rectal, breast, pancreatic, renal cell, and non-small cell lung cancers. one of these antibodies, bevacizumab, has been used with some success as a treatment for Sccs in the head and neck region 44 as well as recurrent cervical tumors. 45 animal studies have shown that in some models of oSSN tumors there is a dramatic upregulation of both veGF-a and veGF-R1t. 46 two recent publications have reported attempts to treat refractory oSSN with intralesional anti-veGF therapy. one involved a case report of a 79-yearold man with a large sessile papillomatous tumor that did not respond to topical or intralesional iFN-2B, topical mmc, or topical 5-FU, and in whom surgical intervention was not recommended secondary to anticoagulant therapy. 47 an intralesional injection of 1.25 mg of bevacizumab was attempted, but after 4 weeks of follow up no change was observed. there were no obvious effects of the treatment noted on pathologic evaluation after excision was finally performed. the second publication, a report on a 2-year trial of subconjunctival ranibizumab as treatment for refractory Scc of the ocular surface included patients who were originally treated with surgery, cryotherapy, topical mmc, and topical iFN-2B; 0.5 mg of ranizumab was injected subconjunctivally every 2 or 4 weeks if the tumor size had remained stable or regressed. three out of the five patients who were enrolled made it through the 24-month study period with no evidence of recurrence. the average number of injections received in the tumors that responded was just over 20 in the 2 year period. one of the cases had an initial response and then a recurrence, and the last patient demonstrated no tumor regression. 48 Neither of the two publications reported any evidence of systemic or severe ocular side effects, but the sample size was small.
Future Directions
as the armamentarium of chemotherapeutic options expands, it is likely other agents will be successfully utilized in the treatment of oSSN. suggested relative indications could include eyes that have greater than two quadrants of conjunctival involvement, greater than 180 degrees of limbal involvement, extension into the visual axis of the cornea, positive margins after excision, and patients who are unable to undergo surgery. 22 currently it is left to the physician's discretion when and how to utilize topical therapies, but there appears to be sufficient evidence to support their use in a variety of clinical situations. more research is needed to further elucidate the ideal treatment algorithm for oSSN and to continue the search for better alternative therapies when needed. n
